Capstone Capital Management Ltd Invests $833,000 in Pfizer Inc. $PFE

Capstone Capital Management Ltd purchased a new stake in Pfizer Inc. (NYSE:PFE) in the first quarter, Holdings Channel.com reports. The firm purchased 29,669 shares of the biopharmaceutical company’s stock, valued at approximately $833,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Vermillion Wealth Management Inc. raised its stake in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the last quarter. Triad Wealth Partners LLC grew its stake in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the last quarter. Eagle Capital Management LLC increased its holdings in shares of Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. increased its holdings in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares in the last quarter. Finally, Mattern Wealth Management LLC raised its position in Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 400 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several research reports. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. CICC Research initiated coverage on Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and cut their price target for the company from $32.00 to $28.00 in a research note on Monday. Bank of America decreased their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Guggenheim lifted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.56.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer continues to draw attention from income investors because of its large dividend payout, and some market commentary frames the stock as a potential value play for buyers seeking yield. How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum
• Positive Sentiment: Analyst and media coverage continues to highlight Pfizer as an attractively priced healthcare stock after the recent FDA approval for IBRANCE, which could support the investment case if pipeline progress continues. Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval?
• Neutral Sentiment: Pfizer is also attracting broad investor attention in screening and “most searched” lists, which reflects heightened trading interest but does not by itself change the fundamentals. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: JPMorgan lowered its price target on Pfizer and kept a neutral stance, signaling limited near-term upside in the bank’s view and likely contributing to the stock’s weakness. Pfizer price target cut news
• Negative Sentiment: Several articles questioned whether Pfizer’s dividend is riskier than it appears, which can dampen enthusiasm even though the stock is known for income appeal. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think
• Negative Sentiment: News coverage about structural problems at Pfizer’s former headquarters added another negative headline, even though one report said the issues were related to construction rather than steel quality. ‘Failures happen during construction’: Office-to-residential conversions are all over NYC, but failures usually get fixed before they get worse

Pfizer Price Performance

Shares of PFE stock opened at $24.05 on Thursday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The stock has a market cap of $137.05 billion, a PE ratio of 18.36 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm’s 50 day moving average price is $25.46 and its two-hundred day moving average price is $26.20.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.